Patent claims for two human genes declared invalid by US court
This article was originally published in RAJ Devices
A US federal district court has ruled that certain patent claims for two human genes – BRCA1 and BRCA2, which are associated with breast and ovarian cancer – are invalid1.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.